AEON Biopharma Sets Annual Shareholder Meeting
AEON Biopharma, a biopharmaceutical company focused on developing ABP-450 as a biosimilar to BOTOX for therapeutic use, announced its Annual Shareholder Meeting will take place on June 17, 2026. The company disclosed a going concern qualification in its 2025 audited financial statements due to liquidity constraints but expects current cash to fund …